Overview
- The FDA said Wednesday its Pharmacy Compounding Advisory Committee will meet July 23–24 to consider allowing seven peptides, including BPC‑157 and TB‑500, to be compounded.
- In 2023 the agency barred more than a dozen peptides from compounding over risks including cancer and liver, kidney, and heart problems, citing sparse human data.
- HHS Secretary Robert F. Kennedy Jr., who says he has used peptides, has urged easing limits and said regulated compounding could pull demand from a gray market of imported “research‑use‑only” vials.
- The compounding panel has vacancies, raising the prospect of new members before July as many earlier advisers who backed restrictions have since left the agency.
- The FDA also plans a second review of additional peptides by February 2027, a step that could shape access for patients and prescribers through compounding pharmacies that make customized drugs outside the standard approval pathway.